Technology | CT Angiography (CTA) | June 29, 2016

New algorithms, cloud-based infrastructure designed to deliver results to clinicians more quickly

HeartFlow, FFR-CT Analysis, next-generation platform, second FDA clearance

June 29, 2016 — HeartFlow Inc. announced that it is launching its next generation of the HeartFlow FFR-CT Analysis. The result of years of development, the next-generation platform includes major advancements in the process and algorithms HeartFlow uses to calculate fractional flow reserve-computed tomography (FFR-CT) values.

 

Watch a video about FFR-CT from ACC.16

 

These technology advancements resulted in the second U.S. Food and Drug Administration (FDA) clearance for HeartFlow’s technology. The company will introduce the next-generation platform to new and existing customers in the coming weeks.

Major enhancements of the new platform include:

  • Advanced algorithms and streamlined case processing, which will provide the HeartFlow Analysis results to clinicians more quickly;
  • Cloud-based infrastructure utilizing Amazon Web Services (AWS), to ensure that delivery of the HeartFlow service is more secure, robust and scalable; and
  • Increased security measures to address the needs of healthcare institutions worldwide.

According to the company, the HeartFlow Analysis is the only non-invasive technology to provide insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart, enabling clinicians to select an appropriate treatment. The technology, which first received de novo clearance from the FDA in 2014, is also available in Canada, Europe and Japan, and has been used to guide the treatment of thousands of patients globally.

“One of the benefits of HeartFlow’s cloud-based platform is that the technology utilizes the data we receive from our global community of clinicians,” said Charles A. Taylor, Ph.D., co-founder and chief technology officer of HeartFlow. “As the number of HeartFlow patients grows, the HeartFlow Analysis continues to improve as we apply deep learning technology to this vast set of data.”

Deep learning involves integrating multiple layers of nonlinear algorithms to help identify patterns and improve understanding of the information. By applying deep learning to large amounts of image data, HeartFlow has the potential to improve the performance with future software releases to help physicians better manage patients with coronary artery disease.

 

Watch a video about how FFR-CT works

For more information: www.heartflow.com


Related Content

News | Cardiac Imaging

May 17, 2024 — The Cum Laude Award-Winning Online Poster presented during the 124th ARRS Annual Meeting found that the ...

Time May 17, 2024
arrow
News | Artificial Intelligence

May 15, 2024 — Heart disease is the leading cause of mortality in the U.S., accounting for one out of every five deaths ...

Time May 15, 2024
arrow
News | Pediatric Imaging

May 15, 2024 — Transfer learning (TL) models trained on heterogeneous public datasets and fine-tuned using institutional ...

Time May 15, 2024
arrow
News | Radiology Business

May 14, 2024 — University Hospitals (UH) and Siemens Healthineers announce a 10-year strategic alliance that builds on ...

Time May 14, 2024
arrow
News | Treatment Planning

May 6, 2024 — Elekta announced the acquisition of Philips Healthcare’s Pinnacle Treatment Planning System (TPS) patent ...

Time May 06, 2024
arrow
News | Pediatric Imaging

May 2, 2024 — Head and abdominal trauma is a leading cause of death for children. About 1%–2% of children who come to ...

Time May 02, 2024
arrow
Feature | Radiology Business

Beginning this spring, ITN will begin sending out a bi-monthly survey to our readers on a variety of topics, which we ...

Time May 02, 2024
arrow
News | Enterprise Imaging

April 25, 2024 — International medical imaging IT and cybersecurity company Sectra has signed two contracts to provide ...

Time April 25, 2024
arrow
News | Radiology Business

April 23, 2024 — A diverse writing group, led by authors at the University of Toronto, have developed an approach for ...

Time April 23, 2024
arrow
News | Clinical Trials

April 16, 2024 — QT Imaging Holdings, Inc., a medical device company engaged in research, development, and ...

Time April 16, 2024
arrow
Subscribe Now